Have Any Questions?

 

Milestones

1991    – Started as Intermed Pharma to manufacture of intermediates.

 

2006    – Commenced manufacturing 1st Oncology API (Capecitabine).

 

2007    – Commenced manufacturing of 1st General API (Efavirenz).

 

2009    – Company name changed as Cdymax (India) Pharma Pvt. Ltd.

 

2011    – New Production Block  (PB-2) commissioned  to manufacture of  Oncology APIs.

 

2013    – Received approval from WHO Geneva for Efavirenz.

 

2014    – Received approval from WHO Geneva for Tenofovir Disoproxil Fumarate.

 

2014    – Received approval from WHO Geneva for Lopinavir.

 

2014    – CEP for Capecitabine from EDQM.

 

2015    – Received facility approval from USFDA for Tenofovir DF and Efavirenz.

 

2016    – Received facility approval from MFDS (KFDA) for Tenofovir DF and Efavirenz.

 

2017    – Received facility approval from Russian Regulatory for Capecitabine.

 

2019    – COFEPRIS – Mexican Authority Audited the oncology facility for the product Erlotinib HCl.

 

2019    – USFDA approved the oncology facility for the product Palbociclib.

 

2019    – WHO audited the facility for the products Tenofovir Disoproxil Fumarate, Atazanavir Sulphate

               

               and Efavirenz.

 

2020    – USFDA approval received for both General and Oncology facility (GMP Audit).